Bolt Biotherapeutics, Inc. (BOLT)
3.89
+0.03
(+0.78%)
USD |
NASDAQ |
Sep 09, 11:40
Bolt Biotherapeutics Enterprise Value : 11.26M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 11.26M |
| September 04, 2026 | 11.34M |
| September 03, 2026 | 11.33M |
| September 02, 2026 | 11.22M |
| September 01, 2026 | 11.67M |
| August 31, 2026 | 11.49M |
| August 28, 2026 | 11.17M |
| August 27, 2026 | 11.53M |
| August 26, 2026 | 11.38M |
| August 25, 2026 | 11.24M |
| August 24, 2026 | 11.03M |
| August 21, 2026 | 10.89M |
| August 20, 2026 | 9.990M |
| August 19, 2026 | 10.11M |
| August 18, 2026 | 9.947M |
| August 17, 2026 | 9.990M |
| August 14, 2026 | 10.28M |
| August 13, 2026 | 10.01M |
| August 12, 2026 | 10.47M |
| August 11, 2026 | 11.49M |
| August 10, 2026 | 11.51M |
| August 07, 2026 | 11.63M |
| August 06, 2026 | 11.28M |
| August 05, 2026 | 11.43M |
| August 04, 2026 | 11.43M |
| Date | Value |
|---|---|
| August 03, 2026 | 11.49M |
| July 31, 2026 | 11.51M |
| July 30, 2026 | 11.32M |
| July 29, 2026 | 11.24M |
| July 28, 2026 | 11.57M |
| July 27, 2026 | 11.48M |
| July 24, 2026 | 11.20M |
| July 23, 2026 | 11.17M |
| July 22, 2026 | 11.70M |
| July 21, 2026 | 11.57M |
| July 20, 2026 | 12.45M |
| July 17, 2026 | 12.34M |
| July 16, 2026 | 11.90M |
| July 15, 2026 | 11.94M |
| July 14, 2026 | 11.63M |
| July 13, 2026 | 11.11M |
| July 10, 2026 | 11.11M |
| July 09, 2026 | 11.49M |
| July 08, 2026 | 11.61M |
| July 07, 2026 | 11.63M |
| July 06, 2026 | 11.55M |
| July 02, 2026 | 11.63M |
| July 01, 2026 | 11.51M |
| June 30, 2026 | 11.24M |
| June 29, 2026 | 6.720M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.79B |
| Oncolytics Biotech, Inc. | 96.67M |
| Sangamo Therapeutics, Inc. | 58.40M |
| Sarepta Therapeutics, Inc. | 2.469B |
| Anixa Biosciences, Inc. | 83.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.72M |
| Revenue (Quarterly) | 0.005M |
| Total Expenses (Quarterly) | 7.725M |
| EPS Diluted (Quarterly) | -4.567 |
| Gross Profit Margin (Quarterly) | -3.32K% |
| Profit Margin (Quarterly) | -154.4K% |
| Earnings Yield | -422.6% |
| Normalized Earnings Yield | -398.56 |